| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5685 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
| filingDate |
1995-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1997-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcc4c61033396164ee7b3ac6a7700762 |
| publicationDate |
1997-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5591736-A |
| titleOfInvention |
Method of retarding the progression of chronic renal failure |
| abstract |
The progression of chronic renal failure in humans may be retarded by administration of dehydroepiandrosterone (DHEA) in effective amounts. The administration of DHEA is preferably oral at a dose of about 400 to 1600 mg/day. Patients suffering from severe chronic renal failure are also preferably maintained on a protein-restricted diet during DHEA administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7960410-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5849740-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6166017-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020194563-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1955700-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003100094-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6642236-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2425715-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7872008-B2 |
| priorityDate |
1995-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |